|
KMID : 0383820120730060303
|
|
Tuberculosis and Respiratory Diseases
2012 Volume.73 No. 6 p.303 ~ p.311
|
|
|
Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study(SELINE)
|
|
Lee Kwan-Ho
Lee Kye-Young
Jeon Young-June
Jung Maan-Hong
Son Choon-Hee
Lee Min-Ki
Ryu Jeong-Seon
Yang Sei-Hoon
Lee Jae-Cheol
Kim Young-Chul
Kim Sun-Young
|
|
|
Abstract
|
|
|
Background: This study was designed to analyze the efficacy of gefitinib as a second-line therapy, according to
the clinical characteristics in Korean patients with non-small-cell lung cancer (NSCLC).
Methods: In this Phase IV observational study, we recruited patients, previously failed first-line chemotherapy, who had locally advanced or metastatic NSCLC, and who were found to be either epidermal growth factor receptor (EGFR) mutation-positive or satisfied 2 or more of the 3 characteristics: adenocarcinoma, female, and non-smoker. These patients were administered with gefitinib 250 mg/day, orally. The primary endpoints were to evaluate the objective response rate (ORR) and to determine the relationship of ORRs, depending on each patient’s characteristics of modified intent-to-treat population.
Results: A total of 138 patients participated in this study. One subject achieved complete response, and 42 subjects achieved partial response (ORR, 31.2%). The subgroup analysis demonstrated that the ORR was significantly higher in patients with EGFR mutation-positive, compared to that of EGFR mutation-negative (45.8% vs. 14.0%, p=0.0004). In a secondary efficacy variable, the median progression-free survival (PFS) was 5.7 months (95% confidence interval, 3.9∼8.4 months) and the 6-month PFS and overall survival were 49.6% and 87.9%, respectively. The most common reported adverse events were rash (34.4%), diarrhea (26.6%), pruritus (17.5%), and cough (15.6%).
Conclusion: Gefitinib was observed in anti-tumor activity with favorable tolerability profile as a second-line therapy in these selected patients. When looking at EGFR mutation status, EGFR mutation-positive showed strong association with gefitinib by greater response and prolonged PFS, compared with that of EGFR mutation-negative.
|
|
|
KEYWORD
|
|
|
Gefitinib, Receptor, Epidermal Growth Factor, Mutation, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|